Objective.-This observational pilot study examined objective circadian phase and sleep timing in chronic migraine (CM) and healthy controls (HC) and the impact of circadian factors on migraine frequency and severity.
INTRODUCTION
Chronic migraine (CM) is a debilitating condition that affects approximately 2% of the general population with a prevalence 2.5-6.5 times higher in women than in men. 1 Sleep disturbance has been identified as a key risk factor in the development and maintenance of CM 2,3 but the biological mechanisms linking sleep and migraine remain unclear.
Studies have found that both increased and decreased sleep time are associated with chronic headaches [3] [4] [5] and daytime naps are a common strategy used to relieve headaches. [6] [7] [8] While most studies have examined the duration or quality of sleep, relatively less attention has been given to examining the timing of sleep or circadian factors in migraine sufferers. Circadian rhythms play an important role in sleep/wake regulation, and emerging evidence suggests that circadian factors might play a role in the etiology of migraine. One animal study found mutations in a component of the molecular circadian clock in connection to migraine. 9 Human studies conducted on migraine sufferers have found a delay in circadian phase [10] [11] [12] and lower levels of plasma melatonin, a key circadian hormone. 10, [13] [14] [15] Furthermore, the administration of melatonin has been shown to prevent or reduce headaches. 11, 12, 16, 17 While previous studies have used invasive measures to assess circadian rhythms, a reliable and noninvasive method of measuring circadian phase is available through saliva collection to examine dim-light melatonin onset (DLMO). 18 DLMO is a biomarker of circadian phase that can be used with other sleep measures to provide information on the alignment between the circadian rhythm and the sleep episode. Circadian misalignment has been investigated in other pain conditions 19, 20 but has not yet been investigated in people with migraine. Therefore, salivary melatonin collection could be a particularly useful method to complement standard sleep assessments to examine both sleep and circadian factors in headache sufferers. The purpose of this study was to investigate objectively measured circadian phase and sleep timing in women with CM compared to age-matched healthy controls (HC). The first aim was to compare CM and HC on sleep timing and circadian factors. The second aim was to examine the impact of the circadian factors on migraine frequency and severity within the CM group. We hypothesized that the CM group would have a delayed circadian phase relative to HC and that greater circadian misalignment would be associated with worse migraine symptoms.
METHODS
Study Design.-The SANDMAN (Sleep Assessment across Night and Day in Migraine and Nonmigraine individuals) project is an observational pilot study consisting of an assessment of habitual sleep at home and an assessment of sleep and circadian phase in a controlled laboratory environment in women with CM and age-matched controls. The overall project aims were to examine the variability of sleep behaviors (eg, timing of bedtimes and rise times) between CM and HC, to characterize the neurobiological correlates of sleep regulation/dysregulation in CM, and to examine the relationship between variability in sleep behaviors, neurobiological correlates, and headache pain. This report is a subset of the SANDMAN project focusing on circadian phase and sleep timing by examining data collected from the circadian assessment in the laboratory and the sleep assessment at home during the 7 days prior to the circadian assessment.
Participants.-Participants were females between 18 and 41 years of age with regular menstrual cycles. All CM participants met the International Classification of Headache Disorders (ICHD-3) criteria 21 with 15 headache days per month for at least 3 months and symptoms meeting criteria for migraine (with or without aura) on at least 8 days per month. HC participants were age-matched (6 3 years) to a CM participant and reported no history of any headache disorders and no more than 1 headache per month during the past 12 months.
Other exclusion criteria for both CM and HC were: (1) unstable medical condition that required immediate treatment, (2) other pain conditions such as chronic low back pain and fibromyalgia, (3) psychiatric condition that required immediate treatment or interfered with the study protocol, (4) daily use medications known to affect melatonin (eg, beta blockers, melatonin pills), (5) use of illicit substances (eg, narcotics, hallucinogens), (6) women who were pregnant or nursing, and (7) travel across more than 3 time zones in the month prior to the study protocol. Participants were recruited through posted advertisements, flyers in neurology and primary care clinics, and a women's health registry list. Screening for eligibility involved a telephone interview followed by an in-person interview that included a review of medical history, the Structured Diagnostic Interview for Headache-Revised (SDIH-R) 22 to assess for headache symptoms, the Structured Diagnostic Interview for DSM-IV (SCID) 23 to assess for psychiatric conditions, and the Duke Structured Interview Schedule for Sleep Disorders 24 to assess for sleep disorders. Diagnosis of migraine was confirmed by a medical exam with the study neurologist (MP). The study was approved by the institutional review board at Rush University Medical Center and all participants provided written informed consent prior to participation.
Measures.-Self-Report Data.-Several self-report measures were collected during the screening visit and the laboratory assessment to characterize the sample. Demographic data were collected during the screening visit. The migraine disability assessment scale (MIDAS), 25 a 5 item questionnaire that measures migraine-related disability over a 3 month period, was used to measure migraine severity. The number of migraine days per month (30 days) from the SDIH-R was used to quantify migraine frequency. The Center for Epidemiological Studies Depression Scale (CES-D) 26 was used to assess depressive symptoms and the State-Trait Anxiety Inventory-Trait (STAI-T) 27 was used to assess trait-levels of anxiety.
Finally, the Morningness-Eveningness Questionnaire (MEQ) 28 was used to measure chronotype, the behavioral manifestation of circadian rhythms based on the individual's preferred schedule. Daily Headache Ratings.-An 11 point numerical rating scale (0 5 no headache, 10 5 extremely painful headache) was used to capture headache frequency and severity. 22, 29 From this scale, a score 2 (at least slightly painful) was used as a cut-off for a "headache day." These ratings were completed daily through the study website as part of the sleep assessment. In addition, participants completed a headache rating at the end of the circadian assessment to determine the headache rating during the day of the circadian assessment. Wrist Actigraphy.-Wrist actigraphy (Actiwatch Spectrum, Phillips Respironics, Bend, OR, USA) was used to measure objective sleep/wake patterns. Participants wore actigraphs for 7 days immediately prior to the in-lab assessment, and concurrently completed daily diaries of sleep and headache ratings for the same 7 days. Actigraphy is commonly used to assess longitudinal sleep/wake patterns and has been well validated as an objective measure of sleep. 30, 31 Participants were instructed to wear the actigraph on the nondominant wrist during the day and night, using the event marker on the device to indicate bed time (ie, lights out) and rise time (ie, lights on). These indicators were used to establish the time in bed (TIB) interval. When no valid event markers were available, any available data (eg, self-report sleep diary data) were used to establish the time in bed. Data were analyzed in 1 minute epochs using medium sensitivity for determining wakefulness with Respironics Actiware version 6.0. Dim Light Melatonin Onset.-As a biomarker of circadian phase, the DLMO from the saliva collection (see procedures below) was calculated for each participant using linear interpolation as the clock time when melatonin concentration levels exceeded a threshold of the mean of 3 consecutive low daytime values (baseline value) plus twice the standard deviation of these 3 values. 32, 33 In addition, the melatonin levels were required to remain above the threshold for at least 2 hours. DLMO is used extensively in human sleep research as a reliable marker of circadian phase.
18,34
Procedures.-Sleep Assessment.-Approximately 7 to 10 days prior to the laboratory (circadian) assessment each participant received an orientation to explain the study procedures. This included instructions for wearing the actigraph 24 hours per day and making daily entries using on-line sleep diaries for the 7 days prior to the circadian assessment. Since the goal was to record habitual sleep/wake patterns, participants were asked to maintain their usual sleep/wake routines during this time. To prepare for the laboratory assessment, participants were also given specific instructions to abstain from certain foods (eg, candy, bananas, popsicles), substances (eg, lipstick), and medications (eg, beta blockers) known to interfere with melatonin production or analysis of saliva. This included abstaining from caffeine (>200 mg) or alcohol in the 24 hours before the laboratory assessment and abstaining from nonsteroidal anti-inflammatory drugs (NSAIDs) in the 72 hours before the laboratory assessment. Participants were also instructed to avoid napping on the day of the laboratory assessment. Circadian Assessment.-Participants arrived at the sleep laboratory 8 hours prior to their habitual bed time, which was determined by calculating the average bed time from the previous 7 days. Upon arrival, participants were screened for alcohol using a breathalyzer. Screening for nicotine, narcotics, and other common drugs of abuse were conducted using a urine drug screen kit. None of the participants tested positive for alcohol or drugs. Beginning 6 hours prior to habitual bedtime, participants remained in dim light < 5 lux, as measured by a light meter (Extech EasyView 31 Light Meter, Nashua, NH, USA), since light exposure can suppress melatonin. Saliva samples were collected every 30 minutes using Salivettes (Sarstedt, Newton, NC, USA). Participants were seated or reclined during the 6 hour sampling period but were not allowed to nap. They were allowed to stand or use the restroom in dim light between samples as needed until 10 minutes before each sample collection. Participants in the migraine group were allowed to take acetaminophen, if needed. Research staff was present to monitor adherence to the protocol throughout the circadian assessment. This protocol follows standard procedures for the collection of DLMO to control factors (ie, light exposure, substances, and daytime naps) known to impact melatonin. 35, 36 Saliva samples were centrifuged immediately following collection and then frozen before they were packed in dry ice and shipped to Solidphase, Inc (Portland, ME, USA) for analysis. Saliva samples were assayed for melatonin through direct radioimmunoassay using standard ALPCO kits with an assay sensitivity of 0.5 pg/mL, intra and interassay CV < 7.5% at 3 pg/mL. Following the last saliva collection, participants were allowed to sleep at their habitual bedtime in the laboratory. Data Analyses.-For each participant, means across the 7 day sleep assessment were used to derive sleep parameters and sleep timing. Technical problems with the actigraph device led to incomplete data for 6 participants (3 HC, 3 CM). The means across 4 days (n 5 1), 5 days (n 5 3), and 6 days (n 5 2) were used for these participants. Sleep parameters derived from the actigraph included sleep onset latency, wake after sleep onset, early morning awakenings, total sleep time, and time in bed (using the method described above). Additionally, sleep efficiency was calculated as the percentage of total sleep time during the period of time in bed. For timing of the sleep phase, the midpoint of the sleep episode was calculated by taking the midpoint of the interval from sleep onset (bed time 1 sleep onset latency) to the rise time. The sleep midpoint does not take into account any time awake within this interval (ie, wake after sleep onset, early morning awakenings). For circadian misalignment, we calculated a phase angle for each participant equal to the time interval from DLMO (circadian phase) to the sleep midpoint (sleep phase). The phase angle has been used as a measure of the circadian misalignment between the DLMO and the midpoint of sleep. 37 Prior to conducting the main analyses, preliminary inspection of the sample characteristics was conducted using descriptive statistics, one-way analysis of variance (ANOVAs), and chi-square tests (see sample characteristics below and Table 1 ). In addition, assumptions for parametric tests were verified using histograms and Levene's test for No statistical power analysis was conducted prior to the study. The sample size was selected based on the availability of the resources from the funding mechanism for this pilot study. All analyses were conducted using SPSS version 24 for Windows.
RESULTS
A total of 65 potential participants were screened for eligibility with 24 CM and 20 HC who qualified for the study. Two CM participants did not complete the assessment protocol and no agematched controls were available for 2 CM participants. Therefore, the final sample size was 20 CM and 20 HC. Two CM did not have a sufficient rise in melatonin using the method described above for calculating DLMO; these participants were excluded from analyses with DLMO and phase angle.
Sample Characteristics.-The average age for the entire sample was 32.4 years, with no significant difference between CM and HC. No significant differences were found on other demographic variables, including ethnicity, race, years of education, relationship status, and employment status (see Table 1 ). As expected, CM used a number of pain medications including abortive medications for migraines (eg, triptans), analgesics, NSAIDs, and opiates. There were no significant differences between groups on use of contraceptives or BMI. Data from the SDIH-R revealed that CM participants reported an average of 23.9 headache days per month with a mean of 18.0 migraine days per month (standard deviation [SD] 5 6.2 days) and 5.9 other headache days per month (eg, tension headache; SD 5 8.2). Typical pain intensity of a migraine was 7.60 (SD 5 1.74) on a scale from 0 (no pain) to 10 (extremely painful). The median number of months with migraines was 60.0 (mean 5 74.3 months). Ten CM participants met criteria for migraine with aura and 10 had migraine without aura. The CM group reported significantly higher scores on the MIDAS compared to the HC group, F(1,38) 5 57.61, P < .001. The CM group also reported more symptoms of depression on the CES-D, F(1,38) 5 14.18, P < .01, and more traitlevel anxiety on the STAI, F(1,38) 5 11.66, P < .01, compared to HC. Also, 20% (n 5 4) of the migraine group reported CES-D 16, a score which indicates clinically elevated symptoms of depression. Using a chi-square test, we found no significant differences between CM and HC on the MEQ, with the majority of participants in both groups endorsing neither morning nor evening preferences. Headache ratings during the sleep assessment revealed a mean rating of 3.95 (SD 5 1.92) for the CM group and a mean rating of 0.21 (SD 5 0.40) for the HC group (median 5 0, IQR 5 0.00-0.42). Using a cut-off of headache rating 2 to indicate a headache day, the CM group reported a mean of 5.15 (SD 5 1.46) headache days (76.6% of days reported). The HC group reported a median of 0 headache days (IQR 5 0.00-0.43; 5.5% of days reported). During the circadian assessment, 17 out of 20 (85%) CM participants reported a headache rating 2, with a mean rating of 4.48 (SD 5 2.72).
Sleep and Circadian Measures.-CM and HC were not significantly different on sleep parameters during the 7 day sleep assessment period (see Table 2 ). During this time, the CM group had an average of 405 minutes of sleep per night compared to 418 minutes of sleep per night in the HC group, but this difference was not significant (P Figure 1 for the relative timing of the circadian and sleep phase. Relationship Between Circadian Factors and Migraine Symptoms.-Within the CM group, the relationship between DLMO and number of migraine days per month was examined with a Pearson coefficient. A significant positive correlation (r 5 .49, n 5 18, P 5 .039) was found, accounting for 24.1% of the shared variance. This indicates that a later melatonin onset was associated with more frequent migraine days per month (see Fig. 2 ). A significant positive correlation was also found between the sleep midpoint and number of migraine days per month (r 5 .47, n 5 20, P 5 .037), accounting for 21.9% of the shared variance. This indicates that a later sleep episode was also associated with more frequent migraine days per month. Finally, a significant positive correlation was found between phase angle and MIDAS DLMO 5 dim-light melatonin onset. Sleep parameters and sleep timing variables are averages based on the 7 days of at-home actigraphy assessment immediately prior to the in-lab assessment. Phase angle is calculated as the time (in hours) from DLMO to sleep midpoint. g 2 5 Eta-squared. 
DISCUSSION
This pilot study investigated the plausibility of circadian dysregulation as a potential factor in the exacerbation of chronic migraines. We did not find support for the hypothesis that individuals with CM would have a delayed circadian phase relative to HC. However, we found that delayed timing of sleep and circadian phase were associated with the frequency of migraines in the CM group, which was consistent with our hypotheses. Specifically, later DLMO and later sleep timing were associated with more migraine days per month and the magnitude of the relationship was in the moderate to large range. Moreover, these associations were present when adjusting for objectively measured total sleep time, indicating that the relationship was not better accounted for by the amount of nocturnal sleep. We also found that greater circadian misalignment, as measured by the phase angle between DLMO and the sleep midpoint, was related to higher scores on the MIDAS, with the magnitude of the correlation considered to be medium to large. Together, these findings indicate that circadian misalignment could play a role in the pathophysiology of CM.
Previously, we proposed a biobehavioral model of chronic headaches and insomnia to explain how coping behaviors for headaches can precipitate and perpetuate sleep disturbances, thereby serving as one potential pathway for increasing the propensity for future headache episodes and the transformation to chronic headaches. 39 Disturbances in the circadian system was proposed as one potential mechanism of sleep disturbance but there was a dearth of studies that assessed circadian phase in migraine sufferers. The present findings provide preliminary evidence for the role of circadian factors in the biobehavioral model, raising the possibility that circadian misalignment could be an exacerbating factor in chronic migraines. Given that headache sufferers often use sleep as a means of coping with headache pain, 6 the palliative use of sleep could lead to irregular sleep times and misalignment with the circadian phase. Furthermore, migraine sufferers might prefer environments with dim light due to photophobia, which could also dysregulate circadian rhythms. Finally, circadian dysregulation could serve as an underlying mechanism that accounts for the frequent comorbidity between chronic migraine and other conditions such as insomnia and mood disorders. In the post hoc analyses, depressive symptoms accounted for some of the variance between circadian phase and migraine symptoms and previous studies have found that delayed circadian phase is associated with an exacerbation of depressive symptoms. 40, 41 Taken together, the present findings serve as a first step in refining the biobehavioral model by revealing a potential circadian pathway which could have an additive effect on migraine frequency and severity when combined with biological predispositions (eg, genetics) and/or environmental factors (eg, stress, sensory stimuli, certain foods). No significant differences and small effect sizes were found between CM and HC on indices of objectively measured sleep disturbance, including total sleep time, sleep efficiency, sleep onset latency, and wake after sleep onset. Previous findings in the literature have been inconsistent when using objective measures of sleep in chronic headaches. 39 Our sample consisted of only women with CM who were age-matched to HC, so it is possible that sex and age moderate the relationship between sleep disturbances and headaches. Another possible explanation is that circadian misalignment rather than sleep disturbance per se might better account for the mechanisms linking sleep and chronic headache. Further research is needed to elucidate the mechanisms of sleep disturbance in chronic headache and to distinguish the impact of circadian factors from the impact of sleep disturbances on migraines. Our findings also have potential clinical implications for the management of migraines. Migraine sufferers with a delayed sleep phase may benefit from an intervention aimed at phase advancement. In a proof-of-concept study using 10 women with fibromyalgia, Burgess et al. 19 demonstrated that bright light treatment in the morning (ie, phototherapy) produced phase advances in circadian timing that were associated with an increase in pain tolerance. For migraine sufferers, circadian phase advancement could be achieved using exogenous melatonin or behavioral modification of sleep schedules (ie, chronotherapy). Previous studies administering oral melatonin have found some success in reducing migraine frequency and severity. 12, 17 Our findings suggest that the mechanism of action in these studies could involve advancement of the circadian phase to an earlier time. Recently, homebased assessment of salivary DLMO has become available and appears to yield reliable results, 35, 42 with the advantages of minimizing time and cost for patients in clinical settings. Given that circadian assessment has been recommended as part of the assessment of headaches, 16 home-based DLMO measures could enhance the precision of delivering chrono-therapeutic treatments for migraine patients. Strengths of this study include using objective measures of sleep and circadian phase and controlling for the effects of age by matching CM with HC. To our knowledge, this is the first study to compare migraine and age-matched controls on circadian phase and sleep timing using salivary DLMO, a reliable biomarker for circadian phase. Our findings appear congruent with previous findings of delayed sleep phase using plasma melatonin in CM, 10, 12 supporting the benefits of using salivary DLMO as a noninvasive biomarker for circadian phase in CM. Some limitations should be considered when interpreting the findings of this study. First, we sought to minimize potential confounds (eg, agerelated changes) by including only women between the ages of 18 and 41. However, this limits the ability to generalize these findings to men with CM or to women in other age groups. In addition, we only selected those who reported at least 15 headache days per month to minimize the variability in migraine occurrence during the protocol. This limits the ability to generalize these findings to those who suffer episodic migraines and precluded analyses on ictal vs interictal states. Given the exploratory nature of our study, we did not adjust for multiple comparisons, which raises the possibility of Type I error. Therefore, our findings should be interpreted as preliminary and further research is needed to examine the reproducibility of these findings. Finally, these findings revealed associations between circadian factors and migraine; however, causation and directionality of the relationship cannot be determined with these data. It is possible that more severe or frequent migraines might contribute to a delay in sleep phase and circadian misalignment.
CONCLUSION
Our findings provide new data that raise the possibility of sleep timing and circadian phase as a potential factor in the pathophysiology of chronic migraine. Given the preliminary nature of these findings, future studies should seek to replicate these findings in a larger sample and conduct hypothesis-driven studies to elucidate the role of circadian factors in migraine. For example, experimental testing of the impact of circadian phase shifting (ie, realignment) on migraine frequency and severity would provide more compelling evidence to demonstrate the connection between circadian rhythms and migraines. Since sleep disturbance is only one factor that can exacerbate migraines, future studies should also examine the potential link between circadian dysregulation and other known exacerbating factors of chronic migraine (eg, obesity, mood disorders).
